Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859496 | 0.86 | TSHR (0.38) | CYP1A2PDE10APDE2ACYP11B2 | |
| SCHEMBL25144512 | 0.82 | MEN1 (0.48) | CA1CA2POLBKMT2ACYP1A2 | |
| SCHEMBL11955048 | 0.79 | NNMT (0.46) | CA1CA2POLBTDP1KMT2A | |
| SCHEMBL9906400 | 0.79 | POLB (0.47) | CA1CA2POLBTDP1KMT2A | |
| SCHEMBL21718908 | 0.78 | HTT (0.35) | CA1CA2POLBTDP1KMT2A | |
| SCHEMBL19154828 | 0.78 | ALOX5AP (0.36) | CA1CA2POLBTDP1KMT2A | |
| SCHEMBL21719172 | 0.78 | POLB (0.34) | POLBTDP1KMT2ASIRT2SIRT1 | |
| SCHEMBL22570331 | 0.78 | POLB (0.34) | POLBTDP1KMT2ASIRT2SIRT1 | |
| SCHEMBL21719170 | 0.78 | HPGD (0.36) | POLBTDP1KMT2ASIRT2SIRT1 | |
| SCHEMBL11955243 | 0.78 | ALOX15 (0.39) | CA1CA2POLBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20210032263-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | CA1 4337/4885CA2 3011/4885POLB 2147/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | CA1 4337/4885CA2 3011/4885POLB 2147/4885 |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | CA1 787/4885CA2 273/4885POLB 4416/4885 |
| US-20210032263-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | CA1 4538/4885CA2 3417/4885POLB 2279/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | CA1 4538/4885CA2 3417/4885POLB 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.